Evaluation of diagnosis and treatment for autoimmune cytopenias
Official title: Evaluation of the Diagnostic/Therapeutic Course of Patients With Autoimmune Cytopenias (Autoimmune Hemolytic Anemia AIHA, Immune Thrombocytopenia ITP, Chronic Idiopathic/Autoimmune Neutropenia CIN/AIN) and Identification of Predictive and Prognostic Markers.
Run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT05931718 · Data updated 2026-11-12
This study is trying to understand how autoimmune cytopenias are diagnosed and treated, looking at different tests and treatments to see what works best for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | June 1, 2019 |
| Main results expected | September 2030 |
| Study ends | June 2035 |
| Registry record updated | October 15, 2024 |
| Trial ID | NCT05931718 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with autoimmune cytopenias.
✕Probably not a fit
Patients with conditions that prevent them from providing informed consent or those diagnosed with immune cytopenia for more than six months prior to enrollment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the diagnostic and therapeutic management of autoimmune cytopenias, including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune neutropenia. It will evaluate traditional and novel diagnostic tools, the types and sequences of therapies administered, response rates, and adverse events. Additionally, it will assess clinical and laboratory predictors of outcomes and the evolution of autoimmune cytopenias into myelodysplastic syndromes. A subgroup of patients with myelodysplastic syndromes will also be included to investigate immunologic events and red cell metabolism.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with autoimmune cytopenias.
How similar studies have gone: While there have been studies on autoimmune cytopenias, this specific approach focusing on a comprehensive evaluation of diagnostic and therapeutic management is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of autoimmune cytopenias (AIHA/ITP/CIN/AIN) * age \>/= 18 years * ability to sign informed consent * availability to undergo 3 year follow up * for the subgroup of patients with myelodysplastic syndrome: bone marrow evaluation showing \>/= 10% dysplastic features of at least one lineage along with MDS defining cytopenia and/or MDS defining cytogenetics. Exclusion Criteria: * any condition impeding the acquisition of the informed consent * immune cytopenia diagnosis preceding \>/= 6 months the enrolment
Where it's running
-
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biological bank for patients with autoimmune cytopenia
This study is setting up a collection of biological samples from patients with autoimmune cytopenia to help researchers learn more about these conditions and find better treatments.
-
Brain network changes in adults with anemia measured by fNIRS
This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.
-
National cohort for pediatric autoimmune cytopenia
This study is trying to gather information about children with autoimmune blood disorders to see how they do over time and what treatments work best for them.
-
Registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
This study is collecting information from adults in France who have recently been diagnosed with immune thrombocytopenia or autoimmune hemolytic anemia to better understand these conditions and how well different treatments work in real life.
-
F182112 in relapsed/refractory autoimmune hemolytic anemia
A small early study tests F182112 as a single treatment for adults with AIHA that has not responded to other therapies, to see if it’s safe and what dose works best.
-
Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome
This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.